News from Medivir’s ongoing R&D day
Medivir is presenting an R&D update this afternoon on oral herpes project Lipsovir (ME 609) and the company’s protease-based projects on Hepatitis C, osteoporosis and COPD (Chronic Obstructive Pulmonary Disease). A short summary will also be given on the status of the spin out process for the company’s HIV projects, Medivir HIV Franchise AB. LABIAL HERPES Lipsovir - phase III to commence already in July Planning and preparations ahead of the start of phase III clinical trials for Lipsovir (ME 609) have proceeded more quickly and more satisfactorily than previously communicated. This means